N-Cbz-glycyl-glycyl-D-phenylalanine

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: N-Cbz-glycyl-glycyl-D-phenylalanine
• 英文别名: (2R)-3-phenyl-2-[[2-[[2-(phenylmethoxycarbonylamino)acetyl]amino]acetyl]amino]propanoic acid
• 化学式: C₂₁H₂₃N₃O₆
• 分子量: 413.4
• InChiKey: PARPWSYTROKYNG-QGZVFWFLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  30
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.24
• 拓扑面积：
  134
• 氢给体数：
  4
• 氢受体数：
  6

文献信息

• ANTI-HER2 ANTIBODY-DRUG CONJUGATE
  申请人：Daiichi Sankyo Company, Limited

  公开号：EP3101032A1

  公开（公告）日：2016-12-07

  As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH- (CH2) n1-La-(CH2)n2-C(=O)- wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the -(CH2)n2-C(=O)-moiety with the nitrogen atom of the amino group at position 1 as the connecting position.

  作为一种抗肿瘤效果和安全性极佳且治疗效果极佳的抗肿瘤药物，本发明提供了一种抗体-药物共轭物，其中下式表示的抗肿瘤化合物通过具有下式表示的结构的连接体与抗 HER2 抗体共轭：-L1-L2-LP-NH-(CH2)n1-La-( )n2-C(=O)-其中，抗 HER2 抗体与末端 L1 连接，抗肿瘤化合物与-( )n2-C(=O)-分子的羰基连接，以位于位置 1 的氨基的氮原子作为连接位置。
• Anti-HER2 antibody-drug conjugate
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US10155821B2

  公开（公告）日：2018-12-18

  As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L1-L2-LP-NH—(CH2)n1-La-(CH2)n2-C(═O)— wherein the anti-HER2 antibody is connected to the terminal L1, and the antitumor compound is connected to the carbonyl group of the —(CH2)n2-C(═O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.

  作为一种抗肿瘤效果和安全性极佳且治疗效果极佳的抗肿瘤药物，本发明提供了一种抗体-药物共轭物，其中下式表示的抗肿瘤化合物通过具有下式表示的结构的连接体与抗 HER2 抗体共轭：-L1-L2-LP-NH-(CH2)n1-La-( )n2-C(═O)-，其中抗 HER2 抗体与末端 L1 连接，抗肿瘤化合物与-( )n2-C(═O)-分子的羰基连接，以 1 位氨基的氮原子为连接位。
• METHOD OF TREATING CANCER COMPRISING ADMINISTRATION OF ANTI-HER2 ANTIBODY-DRUG CONJUGATE
  申请人：DAIICHI SANKYO COMPANY, LIMITED

  公开号：US20200385486A1

  公开（公告）日：2020-12-10

  As an antitumor drug which is excellent in terms of antitumor effect and safety and has an excellent therapeutic effect, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an anti-HER2 antibody via a linker having a structure represented by the following formula: -L 1 -L 2 -L P -NH—(CH 2 )n 1 -L a -(CH 2 )n 2 -C(═O)— wherein the anti-HER2 antibody is connected to the terminal L 1 , and the antitumor compound is connected to the carbonyl group of the —(CH 2 )n 2 -C(═O)— moiety with the nitrogen atom of the amino group at position 1 as the connecting position.